Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2018 | 1 |
2019 | 1 |
2021 | 1 |
2022 | 1 |
2024 | 0 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Showing results for
Mary L. galazka
Your search for
Mary L. Galaska
retrieved no results
Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies.
Mult Scler. 2022 Jan;28(1):111-120. doi: 10.1177/13524585211010294. Epub 2021 May 10.
Mult Scler. 2022.
PMID: 33969750
Free PMC article.
Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis.
Cook S, Leist T, Comi G, Montalban X, Giovannoni G, Nolting A, Hicking C, Galazka A, Sylvester E.
Cook S, et al.
Mult Scler Relat Disord. 2019 Apr;29:157-167. doi: 10.1016/j.msard.2018.11.021. Epub 2018 Nov 20.
Mult Scler Relat Disord. 2019.
PMID: 30885374
Free article.
In general there was no increase in the risk of infections including opportunistic infections with cladribine tablets versus placebo, except for herpes zoster. Periods of severe lymphopenia (< 0.5 10(9) cells/L) were associated with an increased frequency of infections, …
In general there was no increase in the risk of infections including opportunistic infections with cladribine tablets versus placebo, except …
Item in Clipboard
Cite
Cite